Receptor Activator of Nuclear Factor κB Ligand (RANKL)/Osteoprotegerin (OPG) Ratio Is Increased in Severe Osteolysis

Documenti analoghi

• Serum RANKL, osteoprotegerin (OPG), and RANKL/OPG ratio in nephrotic children
  di: Wasilewska, Anna, et al.
  Pubblicazione: (2010)
• RANKL/RANK/OPG: key therapeutic target in bone oncology
  di: Ando, Kosei, et al.
  Pubblicazione: (2008)
• Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers
  di: Martin Widschwendter, et al.
  Pubblicazione: (2015-10-01)
• Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers
  di: Widschwendter, Martin, et al.
  Pubblicazione: (2015)
• Serum proinflammatory cytokines, receptor activator of nuclear factor kappa-Β ligand (RANKL), osteoprotegerin (OPG) and RANKL/OPG ratio in mild and severe COVID-19
  di: Siamak Kazemi-Sufi, et al.
  Pubblicazione: (2024-09-01)